Neumora Therapeutics Launches Phase 1 Study of NMRA-861
NMRA-861 shows potential for superior treatment options.
No adverse effects evident in diverse pre-clinical trials.
WATERTOWN, Mass. — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical innovator, proudly announces the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861. This study will involve healthy adults as well as individuals with stable schizophrenia. NMRA-861 is recognized for its high potency and specificity as a positive allosteric modulator (PAM) of the M4 muscarinic receptor, positioning it as a potential leader in treating schizophrenia and other neuropsychiatric disorders. Preliminary data from this trial is anticipated in early 2026, focusing on safety, tolerability, and pharmacokinetic data suggesting possibilities for daily dosing and central nervous system accessibility.
“We believe that NMRA-861 could serve as a differentiated treatment alternative for several indications, presenting a more favorable therapeutic profile compared to existing antipsychotics and non-selective muscarinic agonists,” stated Dr. Nick Brandon, the company's chief scientific officer. “This Phase 1 study is a pivotal advancement in our M4 drug development program, and we are eager to share our findings next year.”
In prior evaluations, NMRA-861 has demonstrated a remarkable pharmacological profile and effective activity in preclinical efficacy models. Importantly, no convulsions have been noted in trials involving rabbits, dogs, and rats, signaling the compound's safety in different species.
The Challenge of Schizophrenia Treatment
Schizophrenia poses considerable challenges for both patients and healthcare providers. Despite the availability of antipsychotic medications, many patients continue to experience symptoms, underscoring a pressing need for novel treatment strategies. Dr. Christoph Correll, a Clinical Professor of Psychiatry, emphasizes the limitations associated with traditional antipsychotic therapies, such as intolerable side effects and adherence issues. “Addressing these concerns is crucial for enhancing patient care,” he noted.
Targeting M4 receptors represents a transformative strategy in addressing the complexities of schizophrenia treatment. By utilizing allosteric modulation, NMRA-861 aims to achieve increased selectivity for the M4 receptor, potentially translating into better tolerability and effective once-daily dosing.
About NMRA-861
As a promising investigational compound, NMRA-861 is a positive allosteric modulator specifically designed for the M4 muscarinic receptor subtype. Neumora has secured exclusive licensing rights for NMRA-861’s intellectual property from the Warren Center for Neuroscience Drug Discovery at Vanderbilt University, bolstering the potential for its commercialization with a patent extending to 2044. This innovative approach deviates from traditional antipsychotic mechanisms, which primarily involve D2 dopamine receptor blockage. Rather, emerging evidence suggests that M4 receptor targeting can elicit the necessary antipsychotic effects, alleviating the side effects linked to conventional treatment methods.
Understanding Schizophrenia Better
Schizophrenia impacts approximately three million adults in the U.S. and encompasses a spectrum of debilitating symptoms including delusions, hallucinations, and cognitive dysfunction. Many existing therapies are hindered by severe side effects, leading to a significant portion of patients ceasing medication within 18 months due to either inefficacy or intolerable reactions. Neumora’s innovative approaches are geared towards addressing these unmet needs and enhancing the quality of life for individuals affected by this complex disorder.
Neumora’s Mission and Future Directions
Neumora Therapeutics is on a mission to revolutionize the development of treatments for brain diseases. With a robust pipeline composed of seven neuroscience programs, the company is committed to pioneering solutions that target previously underserved neuropsychiatric disorders and neurodegenerative diseases. Their integrated methodology combines translational science, clinical expertise, and advanced computational tools to facilitate precision medicine initiatives, aiming for breakthroughs in treatment outcomes and improved patient quality of life.
For further inquiries, Neumora can be reached through the following contact: Helen Rubinstein at 617-402-5700 or through email at Helen.Rubinstein@neumoratx.com.
Frequently Asked Questions
What is NMRA-861?
NMRA-861 is an investigational positive allosteric modulator targeting the M4 muscarinic receptor, developed by Neumora Therapeutics for schizophrenia treatment.
What are the expected outcomes of the Phase 1 study?
The study aims to assess safety, tolerability, and pharmacokinetics of NMRA-861, potentially supporting its once-daily dosing regimen.
Why is targeting the M4 receptor significant?
Targeting the M4 receptor may lead to improved therapeutic profiles and reduced side effects compared to traditional antipsychotic treatments.
What challenges does schizophrenia treatment currently face?
Current antipsychotics often result in limited effectiveness and serious side effects, leading to medication discontinuation in many patients.
How does Neumora plan to address unmet needs in brain disease treatments?
Neumora's mission focuses on innovative research and novel therapies targeting neuropsychiatric disorders, aiming to improve patient outcomes and quality of life.
